Matthew Gline - 18 Sep 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role: CEO, Director
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
Issuer symbol: ROIV
Transactions as of: 18 Sep 2025
Net transactions value: +$49,957
Form type: 4
Filing time: 18 Sep 2025, 19:28:11 UTC
Previous filing: 22 May 2025
Next filing: 17 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gline Matthew	CEO, Director	C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM	By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline	18 Sep 2025	0001750094

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ROIV	Common Shares	Purchase	$49,957	+3,315	+0.02%	$15.07	17,287,081	18 Sep 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range.